A landmark global trial shows that one dose of the RSVPreF3 OA vaccine protects older adults against serious RSV lung disease for three seasons, raising hopes for long-term protection with just a ...

Due to a law enacted in 2023, Medicare now covers the RSV vaccine for older adults under Part D, which typically covers prescription drugs. This means you shouldn’t incur any out-of-pocket costs.

Cumulatively, the efficacy of a single Arexvy dose to prevent RSV-related lower respiratory tract disease over three RSV seasons was 62.9%. Efficacy over three seasons was 51.1%.

CDC advisors voted to lower the age of RSV vaccination to include people as young as age 50. In the absence of a director, the recommendation will be sent to the CDC chief of staff for consideration.